Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Expands By 16.6%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 798,200 shares, an increase of 16.6% from the May 31st total of 684,800 shares. Based on an average trading volume of 85,900 shares, the short-interest ratio is currently 9.3 days. Currently, 7.3% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

JSPR has been the subject of a number of analyst reports. Royal Bank of Canada started coverage on Jasper Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $70.00 target price for the company. Evercore ISI initiated coverage on shares of Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Oppenheimer restated an “outperform” rating and issued a $80.00 target price on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Finally, TD Cowen began coverage on Jasper Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $67.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at about $3,144,000. Kingdon Capital Management L.L.C. increased its stake in shares of Jasper Therapeutics by 16.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after acquiring an additional 500,000 shares during the last quarter. Fernwood Investment Management LLC raised its holdings in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after acquiring an additional 40,000 shares during the period. Monaco Asset Management SAM acquired a new position in shares of Jasper Therapeutics during the 4th quarter valued at about $197,000. Finally, StemPoint Capital LP purchased a new stake in shares of Jasper Therapeutics in the first quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Up 3.1 %

Shares of JSPR opened at $22.70 on Monday. The company has a market capitalization of $341.86 million, a price-to-earnings ratio of -4.03 and a beta of 2.24. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The stock’s 50-day moving average price is $23.12 and its 200-day moving average price is $19.54.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.23. As a group, equities analysts anticipate that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.